OBI Pharma, Inc. (4174.TWO)
TWD 55.8
(-10.0%)
TWD 55.8
(-10.0%)
| Year | Total Assets | Total Assets Growth |
|---|---|---|
| 2023 | 5.6 Billion TWD | -15.52% |
| 2022 | 6.63 Billion TWD | 47.85% |
| 2021 | 4.48 Billion TWD | -15.98% |
| 2020 | 5.33 Billion TWD | -5.71% |
| 2019 | 5.66 Billion TWD | 20.25% |
| 2018 | 4.7 Billion TWD | -9.26% |
| 2017 | 5.19 Billion TWD | -17.98% |
| 2016 | 6.32 Billion TWD | -13.44% |
| 2015 | 7.31 Billion TWD | 391.3% |
| 2014 | 1.48 Billion TWD | -24.49% |
| 2013 | 1.97 Billion TWD | 125.43% |
| 2012 | 874.17 Million TWD | 67.24% |
| 2011 | 522.71 Million TWD | 0.0% |
| Year | Total Assets | Total Assets Growth |
|---|---|---|
| 2024 Q1 | 5.03 Billion TWD | -10.15% |
| 2024 Q2 | 4.52 Billion TWD | -10.11% |
| 2023 Q1 | 6.81 Billion TWD | 2.74% |
| 2023 FY | 5.6 Billion TWD | -15.52% |
| 2023 Q2 | 6.4 Billion TWD | -5.99% |
| 2023 Q3 | 6.13 Billion TWD | -4.18% |
| 2023 Q4 | 5.6 Billion TWD | -8.73% |
| 2022 FY | 6.63 Billion TWD | 47.85% |
| 2022 Q4 | 6.63 Billion TWD | -5.8% |
| 2022 Q3 | 7.04 Billion TWD | 3.81% |
| 2022 Q2 | 6.78 Billion TWD | -6.17% |
| 2022 Q1 | 7.22 Billion TWD | 61.14% |
| 2021 Q2 | 5.22 Billion TWD | -6.32% |
| 2021 Q1 | 5.57 Billion TWD | 4.41% |
| 2021 Q4 | 4.48 Billion TWD | -8.22% |
| 2021 Q3 | 4.88 Billion TWD | -6.4% |
| 2021 FY | 4.48 Billion TWD | -15.98% |
| 2020 Q1 | 5.26 Billion TWD | -6.97% |
| 2020 Q2 | 5.12 Billion TWD | -2.7% |
| 2020 Q3 | 4.87 Billion TWD | -4.85% |
| 2020 Q4 | 5.33 Billion TWD | 9.47% |
| 2020 FY | 5.33 Billion TWD | -5.71% |
| 2019 Q2 | 6.32 Billion TWD | 37.94% |
| 2019 FY | 5.66 Billion TWD | 20.25% |
| 2019 Q4 | 5.66 Billion TWD | -5.09% |
| 2019 Q3 | 5.96 Billion TWD | -5.66% |
| 2019 Q1 | 4.58 Billion TWD | -2.64% |
| 2018 FY | 4.7 Billion TWD | -9.26% |
| 2018 Q1 | 5.46 Billion TWD | 5.24% |
| 2018 Q4 | 4.7 Billion TWD | -5.81% |
| 2018 Q3 | 4.99 Billion TWD | -7.03% |
| 2018 Q2 | 5.37 Billion TWD | -1.54% |
| 2017 FY | 5.19 Billion TWD | -17.98% |
| 2017 Q4 | 5.19 Billion TWD | -4.65% |
| 2017 Q3 | 5.44 Billion TWD | -4.69% |
| 2017 Q2 | 5.71 Billion TWD | -3.22% |
| 2017 Q1 | 5.9 Billion TWD | -6.75% |
| 2016 Q2 | 6.62 Billion TWD | -1.46% |
| 2016 Q4 | 6.32 Billion TWD | -0.58% |
| 2016 Q3 | 6.36 Billion TWD | -3.94% |
| 2016 FY | 6.32 Billion TWD | -13.44% |
| 2016 Q1 | 6.72 Billion TWD | -8.03% |
| 2015 Q3 | 7.39 Billion TWD | -0.52% |
| 2015 Q4 | 7.31 Billion TWD | -1.17% |
| 2015 Q2 | 7.43 Billion TWD | -1.72% |
| 2015 Q1 | 7.56 Billion TWD | 408.47% |
| 2015 FY | 7.31 Billion TWD | 391.3% |
| 2014 Q1 | - TWD | -100.0% |
| 2014 FY | 1.48 Billion TWD | -24.49% |
| 2014 Q4 | 1.48 Billion TWD | -8.62% |
| 2014 Q3 | 1.62 Billion TWD | -7.11% |
| 2014 Q2 | 1.75 Billion TWD | 0.0% |
| 2013 Q2 | 709.37 Million TWD | 0.0% |
| 2013 FY | 1.97 Billion TWD | 125.43% |
| 2013 Q1 | - TWD | -100.0% |
| 2013 Q4 | 1.97 Billion TWD | 0.0% |
| 2012 Q3 | 874.17 Million TWD | 0.0% |
| 2012 Q4 | 874.17 Million TWD | 0.0% |
| 2012 FY | 874.17 Million TWD | 67.24% |
| 2011 FY | 522.71 Million TWD | 0.0% |
| Name | Total Assets | Total Assets Difference |
|---|---|---|
| Anti-Microbial Savior BioteQ Co., Ltd | 128.04 Million TWD | -4276.432% |
| SYN-TECH Chem. & Pharm. Co., Ltd. | 2.9 Billion TWD | -93.178% |
| Level Biotechnology Inc. | 822.67 Million TWD | -581.181% |
| Sagittarius Life Science Corp | 664.72 Million TWD | -743.041% |
| NeoCore Technology Co., Ltd. | 548.74 Million TWD | -921.214% |
| TaiMed Biologics Inc. | 3.89 Billion TWD | -43.914% |
| GlycoNex Incorporation | 1.55 Billion TWD | -260.886% |
| VBI | 452.1 Million TWD | -1139.519% |
| GeneReach Biotechnology Corp. | 1.17 Billion TWD | -376.464% |
| Taiwan Advance Bio-Pharmaceutical Inc. | 748.57 Million TWD | -648.612% |
| SynCore Biotechnology Co.,Ltd | 378.36 Million TWD | -1381.092% |
| Genomics BioSci & Tech. Co.,Ltd. | 1.13 Billion TWD | -394.238% |
| Visgeneer Inc. | 397.17 Million TWD | -1310.934% |
| Mycenax Biotech Inc. | 3.77 Billion TWD | -48.628% |
| Sunmax Biotechnology Co., Ltd. | 2.15 Billion TWD | -159.556% |
| G&E Herbal Biotechnology Co., Ltd. | 883.09 Million TWD | -534.574% |
| Neith Corporation | 192.15 Million TWD | -2816.369% |
| Medigen Vaccine Biologics Corporation | 6.09 Billion TWD | 8.022% |
| TaiwanJ Pharmaceuticals Co., Ltd. | 73.55 Million TWD | -7518.328% |
| Enimmune corporation | 604.82 Million TWD | -826.528% |
| TaiRx, Inc. | 833.74 Million TWD | -572.134% |
| CHO Pharma, Inc. | 3.08 Billion TWD | -81.589% |
| EirGenix Inc. | 11.16 Billion TWD | 49.797% |
| BioLASCO Taiwan Co., Ltd. | 573.13 Million TWD | -877.754% |
| Sunny Pharmtech Inc. | 1.71 Billion TWD | -227.261% |
| Lin BioScience, Inc. | 3.59 Billion TWD | -55.805% |
| BioGend Therapeutics Co., Ltd. | 1.05 Billion TWD | -433.459% |
| Feng Chi Biotech Corp. | 301.03 Million TWD | -1761.56% |
| Bio Preventive Medicine Corp. | 264.65 Million TWD | -2017.416% |
| Lukas Biomedical Inc. | 441.19 Million TWD | -1170.173% |
| RBC Bioscience Corporation | 753.79 Million TWD | -643.429% |
| BiOptic Inc. | 613.77 Million TWD | -813.023% |
| BRIM Biotechnology, Inc. | 1.77 Billion TWD | -215.061% |
| Shine-On BioMedical Co.,Ltd. | 1.15 Billion TWD | -383.213% |
| Great Novel Therapeutics Biotech & Medicals | 644.84 Million TWD | -769.024% |
| Syngen Biotech Co.,Ltd. | 3.1 Billion TWD | -80.407% |
| Advagene Biopharma Co., Ltd. | 147.93 Million TWD | -3688.101% |
| NaviFUS Corp. | 490.53 Million TWD | -1042.404% |
| Gwo Xi Stem Cell Applied Technology Co. , Ltd | 1.22 Billion TWD | -357.193% |
| Sinew Pharma Inc. | 1.36 Billion TWD | -311.031% |
| Andros Pharmaceuticals Co.,Ltd | 529.14 Million TWD | -959.044% |
| Greenyn Biotechnology Co., Ltd | 1.16 Billion TWD | -382.517% |
| Lumosa Therapeutics Co., Ltd. | 1.65 Billion TWD | -238.342% |
| AP Biosciences Inc | 890.75 Million TWD | -529.116% |
| Medigen Biotechnology Corp. | 8.52 Billion TWD | 34.283% |
| 3D Global Biotech Inc. | 324.14 Million TWD | -1628.806% |
| Pharmosa Biopharm Inc. | 1.33 Billion TWD | -320.194% |
| Intech Biopharm Corporation | 2.71 Billion TWD | -106.704% |
| Oneness Biotech Co., Ltd. | 15.36 Billion TWD | 63.525% |
| Eusol Biotech Co.,Ltd. | 410.25 Million TWD | -1265.943% |
| TWi Biotechnology, Inc. | 396.85 Million TWD | -1312.089% |
| Ever Supreme Bio Technology Co., Ltd | 2.07 Billion TWD | -169.947% |
| TCI GENE Inc. | 1.16 Billion TWD | -380.633% |
| MegaPro Biomedical Co., Ltd | 294.58 Million TWD | -1802.326% |
| Senhwa Biosciences, Inc. | 1.36 Billion TWD | -311.044% |
| Taiwan Bio Therapeutics Co., Ltd | 941.76 Million TWD | -495.044% |
| NatureWise Biotech & Medicals Corporation | 698.45 Million TWD | -702.331% |
| PharmaEngine, Inc. | 3.95 Billion TWD | -41.73% |
| Savior Lifetec Corporation | 3.82 Billion TWD | -46.596% |
| TaiGen Biopharmaceuticals Holdings Limited | 1.22 Billion TWD | -355.661% |
| Meribank Biotech Co., Ltd | 1.06 Billion TWD | -427.669% |
| Acepodia, Inc. | 6.81 Billion TWD | 17.814% |
| Caliway Biopharmaceuticals Co., Ltd. | 3.82 Billion TWD | -46.449% |